FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:602-605 March 3, 1994 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Castleman's disease (angiofollicular lymphoid hyperplasia) is a heterogeneous group of lymphoproliferative disorders of uncertain cause¹. Two pathologic types, hyaline vascular and plasma-cell disease, have been recognized. The plasma-cell variant of Castleman's disease may be localized or multicentric. Multicentric disease is a systemic lymphoproliferative disorder characterized by lymphadenopathy, hepatosplenomegaly, and constitutional symptoms. Anemia, hypoalbuminemia, and hypergammaglobulinemia are also common. Interleukin-6, a cytokine with pleiotropic effects on the immune system, hematopoiesis, and acute-phase reactions, is a putative growth factor in multiple myeloma and may also be central to the pathophysiology of Castleman's disease^2,3,4,5,6,7. Administration of a murine anti-interleukin-6 monoclonal antibody . . . [Full Text of this Article]

Methods

Case Report

Discussion

Source Information

From the Departments of Medicine and Pathology, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences (J.T.B., D.V., K.H., S.J., B.B.), and the Department of Pathology, John L. McClellan Memorial Veterans Hospital (S.-M.H.) -- both in Little Rock; the Department of Hematology, Centre Hospitalier Universitaire, Nantes, France (R.B., B.K.); and the Innotherapie Laboratoires, Besancon, France (J.W.).

Address reprint requests to Dr. Barlogie at the University of Arkansas for Medical Sciences, Slot 508, 4301 W. Markham, Little Rock, AR 72205.

References

This article has been cited by other articles:

• Shen, H., Goldstein, D. R. (2009). IL-6 and TNF-{alpha} Synergistically Inhibit Allograft Acceptance. J. Am. Soc. Nephrol. 20: 1032-1040 [Abstract] [Full Text]  
• Scadden, D. T., Muse, V. V., Hasserjian, R. P. (2006). Case records of the Massachusetts General Hospital. Case 30-2006. A 41-year-old man with dyspnea, fever, and lymphadenopathy.. NEJM 355: 1358-1368 [Full Text]  
• Montani, D., Achouh, L., Marcelin, A. G., Viard, J-P., Hermine, O., Canioni, D., Sitbon, O., Simonneau, G., Humbert, M. (2005). Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. Eur Respir J 26: 969-972 [Abstract] [Full Text]  
• Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., Hara, M., Taguchi, H., Kimura, Y., Kato, Y., Asaoku, H., Kumagai, S., Kodama, F., Nakahara, H., Hagihara, K., Yoshizaki, K., Kishimoto, T. (2005). Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106: 2627-2632 [Abstract] [Full Text]  
• Dagna, L., Broccolo, F., Paties, C. T., Ferrarini, M., Sarmati, L., Praderio, L., Sabbadini, M. G., Lusso, P., Malnati, M. S. (2005). A Relapsing Inflammatory Syndrome and Active Human Herpesvirus 8 Infection. NEJM 353: 156-163 [Abstract] [Full Text]  
• George, D. J., Halabi, S., Shepard, T. F., Sanford, B., Vogelzang, N. J., Small, E. J., Kantoff, P. W. (2005). The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480. Clin. Cancer Res. 11: 1815-1820 [Abstract] [Full Text]  
• Bachetti, T., Comini, L., Pasini, E., Ferrari, R. (2004). Anti-cytokine therapy in chronic heart failure: new approaches and unmet promises. Eur Heart J Suppl 6: F16-F21 [Abstract] [Full Text]  
• Jung, C. P., Horster, S., Lohse, P., Bogner, J. R., Emmerich, B., Goebel, F. D. (2003). Uncommon Hematologic Malignancies: CASE 1. PLASMABLASTIC LEUKEMIA IN HIV-ASSOCIATED MULTICENTRIC CASTLEMAN'S DISEASE. JCO 21: 4248-4249 [Full Text]  
• Goedert, J. J. (2003). Multicentric Castleman disease: viral and cellular targets for intervention. Blood 102: 2710-2711 [Full Text]  
• Wilkinson, S., Forrester-Wood, C. P. (2003). Surgical resection of a solitary plasmacytoma originating in a rib of a patient with Castleman's disease. Ann. Thorac. Surg. 75: 1018-1019 [Abstract] [Full Text]  
• Deng, H., Chu, J. T., Rettig, M. B., Martinez-Maza, O., Sun, R. (2002). Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression. Blood 100: 1919-1921 [Abstract] [Full Text]  
• Li, H., Nicholas, J. (2002). Identification of Amino Acid Residues of gp130 Signal Transducer and gp80 {alpha} Receptor Subunit That Are Involved in Ligand Binding and Signaling by Human Herpesvirus 8-Encoded Interleukin-6. J. Virol. 76: 5627-5636 [Abstract] [Full Text]  
• Lachmann, H.J., Gilbertson, J.A., Gillmore, J.D., Hawkins, P.N., Pepys, M.B. (2002). Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM 95: 211-218 [Abstract] [Full Text]  
• Oksenhendler, E., Boulanger, E., Galicier, L., Du, M.-Q., Dupin, N., Diss, T. C., Hamoudi, R., Daniel, M.-T., Agbalika, F., Boshoff, C., Clauvel, J.-P., Isaacson, P. G., Meignin, V. (2002). High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99: 2331-2336 [Abstract] [Full Text]  
• Corbellino, M., Bestetti, G., Scalamogna, C., Calattini, S., Galazzi, M., Meroni, L., Manganaro, D., Fasan, M., Moroni, M., Galli, M., Parravicini, C. (2001). Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98: 3473-3475 [Abstract] [Full Text]  
• Zagury, D., Burny, A., Gallo, R. C. (2001). Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines. Proc. Natl. Acad. Sci. USA 98: 8024-8029 [Abstract] [Full Text]  
• Curioni, S., D'Amico, M., Quartagno, R., Martino, S., Dell'Antonio, G., Cusi, D. (2001). Castleman's disease with nephrotic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant 16: 1475-1478 [Full Text]  
• De Benedetti, F., Pignatti, P., Vivarelli, M., Meazza, C., Ciliberto, G., Savino, R., Martini, A. (2001). In Vivo Neutralization of Human IL-6 (hIL-6) Achieved by Immunization of hIL-6-Transgenic Mice with a hIL-6 Receptor Antagonist. J. Immunol. 166: 4334-4340 [Abstract] [Full Text]  
• Du, M.-Q., Liu, H., Diss, T. C., Ye, H., Hamoudi, R. A., Dupin, N., Meignin, V., Oksenhendler, E., Boshoff, C., Isaacson, P. G. (2001). Kaposi sarcoma-associated herpesvirus infects monotypic (IgM{lambda}) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97: 2130-2136 [Abstract] [Full Text]  
• Haddad, E., Paczesny, S., Leblond, V., Seigneurin, J.-M., Stern, M., Achkar, A., Bauwens, M., Delwail, V., Debray, D., Duvoux, C., Hubert, P., de Ligny, B. H., Wijdenes, J., Durandy, A., Fischer, A. (2001). Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 97: 1590-1597 [Abstract] [Full Text]  
• Nishimoto, N., Kishimoto, T., Yoshizaki, K. (2000). Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 59: i21-27 [Abstract] [Full Text]  
• Oksenhendler, E., Carcelain, G., Aoki, Y., Boulanger, E., Maillard, A., Clauvel, J.-P., Agbalika, F. (2000). High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 96: 2069-2073 [Abstract] [Full Text]  
• Greiner, T., Armitage, J. O., Gross, T. G. (2000). Atypical Lymphoproliferative Diseases. ASH Education Book 2000: 133-146 [Abstract] [Full Text]  
• Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., Kishimoto, T., Yoshizaki, K. (2000). Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95: 56-61 [Abstract] [Full Text]  
• Watkins, J. B., Graeme-Cook, F. M., Samuels, J. (1999). Case 25-1999- A 16-Year-Old Boy with Recurrent Abdominal Pain. NEJM 341: 593-599 [Full Text]  
• Aoki, Y., Jaffe, E. S., Chang, Y., Jones, K., Teruya-Feldstein, J., Moore, P. S., Tosato, G. (1999). Angiogenesis and Hematopoiesis Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6. Blood 93: 4034-4043 [Abstract] [Full Text]  
• Belec, L., Mohamed, A. S., Authier, F.-J., Hallouin, M.-C., Soe, A. M., Cotigny, S., Gaulard, P., Gherardi, R. K. (1999). Human Herpesvirus 8 Infection in Patients With POEMS Syndrome-Associated Multicentric Castleman's Disease. Blood 93: 3643-3653 [Abstract] [Full Text]  
• Rebouissou, C., Wijdenes, J., Autissier, P., Tarte, K., Costes, V., Liautard, J., Rossi, J.-F., Brochier, J., Klein, B. (1998). A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma. Blood 91: 4727-4737 [Abstract] [Full Text]  
• Molden, J., Chang, Y., You, Y., Moore, P. S., Goldsmith, M. A. (1997). A Kaposi's Sarcoma-associated Herpesvirus-encoded Cytokine Homolog (vIL-6) Activates Signaling through the Shared gp130 Receptor Subunit. J. Biol. Chem. 272: 19625-19631 [Abstract] [Full Text]  
• Salvati, A. L., Lahm, A., Paonessa, G., Ciliberto, G., Toniatti, C. (1995). Interleukin-6 (IL-6) Antagonism by Soluble IL-6 Receptor [IMAGE] Mutated in the Predicted gp130-binding Interface. J. Biol. Chem. 270: 12242-12249 [Abstract] [Full Text]